Acinetobacter baumannii in the critically ill: complex infections get complicated
Acinetobacter baumannii is increasingly associated with various epidemics, representing a serious concern due to the broad level of antimicrobial resistance and clinical manifestations. During the last decades, A. baumannii has emerged as a major pathogen in vulnerable and critically ill patients. B...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1196774/full |
| _version_ | 1797797818562248704 |
|---|---|
| author | Ilaria Cavallo Alessandra Oliva Rebecca Pages Francesca Sivori Mauro Truglio Giorgia Fabrizio Martina Pasqua Fulvia Pimpinelli Enea Gino Di Domenico |
| author_facet | Ilaria Cavallo Alessandra Oliva Rebecca Pages Francesca Sivori Mauro Truglio Giorgia Fabrizio Martina Pasqua Fulvia Pimpinelli Enea Gino Di Domenico |
| author_sort | Ilaria Cavallo |
| collection | DOAJ |
| description | Acinetobacter baumannii is increasingly associated with various epidemics, representing a serious concern due to the broad level of antimicrobial resistance and clinical manifestations. During the last decades, A. baumannii has emerged as a major pathogen in vulnerable and critically ill patients. Bacteremia, pneumonia, urinary tract, and skin and soft tissue infections are the most common presentations of A. baumannii, with attributable mortality rates approaching 35%. Carbapenems have been considered the first choice to treat A. baumannii infections. However, due to the widespread prevalence of carbapenem-resistant A. baumannii (CRAB), colistin represents the main therapeutic option, while the role of the new siderophore cephalosporin cefiderocol still needs to be ascertained. Furthermore, high clinical failure rates have been reported for colistin monotherapy when used to treat CRAB infections. Thus, the most effective antibiotic combination remains disputed. In addition to its ability to develop antibiotic resistance, A. baumannii is also known to form biofilm on medical devices, including central venous catheters or endotracheal tubes. Thus, the worrisome spread of biofilm-producing strains in multidrug-resistant populations of A. baumannii poses a significant treatment challenge. This review provides an updated account of antimicrobial resistance patterns and biofilm-mediated tolerance in A. baumannii infections with a special focus on fragile and critically ill patients. |
| first_indexed | 2024-03-13T03:54:08Z |
| format | Article |
| id | doaj.art-b57c7870170f4562894c2e1f75dc509d |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-03-13T03:54:08Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-b57c7870170f4562894c2e1f75dc509d2023-06-22T07:58:40ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2023-06-011410.3389/fmicb.2023.11967741196774Acinetobacter baumannii in the critically ill: complex infections get complicatedIlaria Cavallo0Alessandra Oliva1Rebecca Pages2Francesca Sivori3Mauro Truglio4Giorgia Fabrizio5Martina Pasqua6Fulvia Pimpinelli7Enea Gino Di Domenico8Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, ItalyMicrobiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyMicrobiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyMicrobiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyMicrobiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyDepartment of Biology and Biotechnology "C. Darwin" Sapienza University of Rome, Rome, ItalyMicrobiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyDepartment of Biology and Biotechnology "C. Darwin" Sapienza University of Rome, Rome, ItalyAcinetobacter baumannii is increasingly associated with various epidemics, representing a serious concern due to the broad level of antimicrobial resistance and clinical manifestations. During the last decades, A. baumannii has emerged as a major pathogen in vulnerable and critically ill patients. Bacteremia, pneumonia, urinary tract, and skin and soft tissue infections are the most common presentations of A. baumannii, with attributable mortality rates approaching 35%. Carbapenems have been considered the first choice to treat A. baumannii infections. However, due to the widespread prevalence of carbapenem-resistant A. baumannii (CRAB), colistin represents the main therapeutic option, while the role of the new siderophore cephalosporin cefiderocol still needs to be ascertained. Furthermore, high clinical failure rates have been reported for colistin monotherapy when used to treat CRAB infections. Thus, the most effective antibiotic combination remains disputed. In addition to its ability to develop antibiotic resistance, A. baumannii is also known to form biofilm on medical devices, including central venous catheters or endotracheal tubes. Thus, the worrisome spread of biofilm-producing strains in multidrug-resistant populations of A. baumannii poses a significant treatment challenge. This review provides an updated account of antimicrobial resistance patterns and biofilm-mediated tolerance in A. baumannii infections with a special focus on fragile and critically ill patients.https://www.frontiersin.org/articles/10.3389/fmicb.2023.1196774/fullAcinetobacter baumanniicancerbiofilmskin and soft-tissue infectionscolistincarbapenem |
| spellingShingle | Ilaria Cavallo Alessandra Oliva Rebecca Pages Francesca Sivori Mauro Truglio Giorgia Fabrizio Martina Pasqua Fulvia Pimpinelli Enea Gino Di Domenico Acinetobacter baumannii in the critically ill: complex infections get complicated Frontiers in Microbiology Acinetobacter baumannii cancer biofilm skin and soft-tissue infections colistin carbapenem |
| title | Acinetobacter baumannii in the critically ill: complex infections get complicated |
| title_full | Acinetobacter baumannii in the critically ill: complex infections get complicated |
| title_fullStr | Acinetobacter baumannii in the critically ill: complex infections get complicated |
| title_full_unstemmed | Acinetobacter baumannii in the critically ill: complex infections get complicated |
| title_short | Acinetobacter baumannii in the critically ill: complex infections get complicated |
| title_sort | acinetobacter baumannii in the critically ill complex infections get complicated |
| topic | Acinetobacter baumannii cancer biofilm skin and soft-tissue infections colistin carbapenem |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1196774/full |
| work_keys_str_mv | AT ilariacavallo acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT alessandraoliva acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT rebeccapages acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT francescasivori acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT maurotruglio acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT giorgiafabrizio acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT martinapasqua acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT fulviapimpinelli acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated AT eneaginodidomenico acinetobacterbaumanniiinthecriticallyillcomplexinfectionsgetcomplicated |